Aaron Lammers
Medical · Detroit, MINPI 1417407438
Payments from drug & device makers
Across 253 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$591
- Lundbeck LLC$430
- Otsuka America Pharmaceutical, Inc.$409
- Novo Nordisk$406
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$404
- Lilly USA, LLC$341
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,635100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $591 |
| Lundbeck LLC | 25 | $430 |
| Otsuka America Pharmaceutical, Inc. | 20 | $409 |
| Novo Nordisk | 24 | $406 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $404 |
| Lilly USA, LLC | 22 | $341 |
| AstraZeneca | 12 | $309 |
| Pfizer | 20 | $285 |
| Dexcom, Inc. | 15 | $230 |
| GSK | 11 | $178 |
| Boehringer Ingelheim | 8 | $169 |
| Exact Sciences | 8 | $156 |
| Abbott | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $84 |
| Merck | 4 | $83 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Neurocrine Biosciences, Inc. | 3 | $52 |
| Johnson & Johnson | 2 | $46 |
| Bayer | 2 | $42 |
| Novartis | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Alkermes, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,635 in reported general payments places this provider in the 85th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 207 | $140,180 |
| FarxigaDapagliflozin Propanediol | 93 | $62,506 |
| JardianceEmpagliflozin | 54 | $45,883 |
| EliquisApixaban | 58 | $36,984 |
| TrulicityDulaglutide | 36 | $32,943 |
| RexultiBrexpiprazole | 12 | $28,587 |
| EntrestoSacubitril/Valsartan | 34 | $23,240 |
| OzempicSemaglutide | 14 | $16,397 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 277 | $9,912 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $8,122 |
| Varenicline Tartrate | 33 | $7,801 |
| BrilintaTicagrelor | 15 | $6,446 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,410 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $5,680 |
| Ventolin HfaAlbuterol Sulfate | 102 | $5,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta | $178 | $146,590227 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $309 | $74,632134 claims |
| Boehringer IngelheimJardiance | $169 | $45,88354 claims |
| PfizerEliquis | $285 | $36,98458 claims |
| Lilly USA, LLCTrulicity | $341 | $32,94336 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $409 | $28,58712 claims |
| NovartisEntresto | $40 | $23,24034 claims |
| Novo NordiskOzempic | $406 | $16,39714 claims |
| AbbVieSynthroid | $591 | $62813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 755 medical providers in Michigan.
Other medical in Detroit
- John BrabantDetroit$26K
- Kimberly BelzerDetroit$16K
- Linda RyznarDetroit$16K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.